[1] Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg, 2019, 154:209-217. [2] Zhang K, Song P, Gao J, et al. Perspectives on a combined test of multi serum biomarkers in China: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Drug Discov Ther, 2014, 8:102-109. [3] Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol, 2011, 21:401-416. [4] Zhou J, Tang ZY, Wu ZQ, et al. Factors influencing survival in hepatocellular carcinoma patients with macroscopic portal vein tumor thrombosis after surgery, with special reference to time dependency: a single-center experience of 381 cases. Hepatogastroenterology, 2006, 53:275-280. [5] Li T, Qin LX, Gong X, et al. Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma. Surgery, 2014, 156:651-660. [6] Li T, Qin LX, Gong X, et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer, 2013, 119:126-135. [7] Chen JY, Chau GY, Lui WY, et al. Clinicopathologic features and factors related to survival of patients with small hepatocellular carcinoma after hepatic resection. World J Surg, 2003, 27:294-298. [8] Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surg, 2016, 151:356-363. [9] Peng Z, Chen S, Xiao H, et al. Microvascular invasion as a predictor of response to treatment with Sorafenib and transarterial chemoembolization for recurrent intermediate-stage hepatocellular carcinoma. Radiology, 2019, 292:237-247. [10] 中国抗癌协会肝癌专业委员会, 中华医学会肝病会分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015 年版). 临床肝胆病杂志, 2015, 31:833-839. [11] Liao M, Qin W, Liao Y, et al. Prognostic value of gamma-glutamyl transpeptidase to lymphocyte count ratio in patients with single tumor size≤ 5 cm hepatocellular carcinoma after radical resection. Front Oncol, 2019, 9:347. [12] Ke R, Lv L, Li J, et al. Prognostic value of heterogeneous ribonucleoprotein A1 expression and inflammatory indicators for patients with surgically resected hepatocellular carcinoma: Perspectives from a high occurrence area of hepatocellular carcinoma in China. Oncol Lett, 2018, 16:3746-3756. [13] 曹国良, 蔡庆, 李幼安, 等. 肝细胞癌微血管侵犯的危险因素分析及预后. 中华消化外科杂志, 2017, 16:1048-1052. [14] Yin CQ, Yuan CH, Qu Z, et al. Liquid biopsy of hepatocellular carcinoma: circulating tumor-derived biomarkers. Dis Markers, 2016, 2016:1427849. [15] 何旭昶, 安文慧, 曾庆彬, 等. 微血管侵犯分级对肝细胞癌行根治性肝切除术后早期复发的预测价值. 临床肝胆病杂志, 2020, 36: 1757-1762. |